Chemical Structure (Anastrozole 01)
Anastrozole Tablet
Product Images NDC 71335-1879
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 71335-1879). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Anastrozole 02)
The text is presenting cancer-related data, showing the disease-free survival in months for two treatments: anastrozole and tamoxifen. The data is displayed in a graphic, where the y-axis represents the proportion of patients alive and disease-free, and the x-axis shows the duration of the treatment measured in months. In addition, there is a table showing the number of patients at risk for each treatment at different points in time.*
Figure 2 (Anastrozole 03)
This appears to be a visual representation of a study or experiment comparing the disease-free survival rates of patients receiving either anastrozole or tamoxifen. The y-axis measures the proportion of patients who remain disease-free over time (in months), and the x-axis lists the time intervals. The chart includes two lines representing the two groups being compared, and a table indicating the number of patients at risk in each group at various time intervals.*
Figure 3 (Anastrozole 04)
This seems to be a graph depicting the Kaplan-Meier curves representing the time to an event over a span of 120 months. The randomised treatment options are Anastrozole and Tamoxifen. The number of patients at risk is shown on the vertical axis, however, it has been truncated to improve clarity. There is some text above and below the graph that cannot be read properly.*
Figure 4 (Anastrozole 05)
This appears to be a graph with the title "PROPORTION EVENT FREE" and the subtitle "RANDOMISED TREATMENT ANASTROZOLE" and "TAMOXIFEN". It shows the time to event in months, with each month from 0 to 120 displayed on the graph. The horizontal axis shows the percentage of patients screened, and the vertical axis shows the number of patients at risk. The graph appears to display two curves labeled "Anastrozole" and "Tamoxifen". However, the values and information presented in this text are incomplete, and it is not possible to provide a more specific description without additional information.*
Figure 5 (Anastrozole 06)
The text appears to be a graph showing the time to progression in months for a randomized treatment using anastrozole and tamoxifen. The graph shows that progression is not occurring at a consistent rate over time. The number of patients at risk at each time point is also included in the graph.*
Figure 6 (Anastrozole 07)
This is a graph showing a comparison between two different substances, Anastrozole and Tamoxifen, over four months regarding time to progression, with the x-axis displaying the specific month, and the y-axis showing the number of months to progression. The graph is displaying the proportion that is not progressing. There are also numbers on the bottom of the graph showcasing the months being measured at intervals of 2. The data was obtained through a randomized treatment of patients. A risk analysis showing the number of patients still under observation at each month is displayed at the bottom of the graph.*
Label (Lbl713351879)
This is a medication called Anastrozole and each tablet contains 1 mg of the medication. The tablets are white, round in shape and imprinted with "AN:1". The medication is stored at room temperature between 20-25 C (68-77 F) and in a container that complies with USP standards. The medication should be kept away from the reach of children and in a light-resistant container. The text also provides information about the manufacturer (Natco Pharma Limited) and the expiry date (MM/YY) but no information is given about the condition that the medication is used to treat.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
